Skip to content
ParcelBio logo

ParcelBio

Hiring

ParcelBio is a YC Winter 2024 (W24) company. Team of 5.

About ParcelBio

GPAgent's own fund-neutral profile, written from public information. Updated Oct 5, 2026.

Summary

ParcelBio develops APEXm, an engineered mRNA platform that produces higher peak protein expression and sustains it longer than conventional mRNA, hitting therapeutic thresholds that standard RNA technologies cannot reach. The platform uses proprietary RNA domains to recruit the cell's native stabilizing machinery, making it modular across any encoded protein and any target cell type. Lead programs focus on in vivo CAR-T for autoimmune disease and oncology, replacing approaches limited by insufficient potency or durability.

From the Y Combinator listing

How ParcelBio describes itself in Y Combinator's public directory. Original listing (opens in a new tab)

Next-generation mRNA medicines

ParcelBio is delivering the next generation of RNA medicines.

Facts

Industry
Healthcare / Healthcare -> Therapeutics
Team size
5
Status
Active
Stage
Early

Founders (2)

Score every batch against your own thesis

GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.

How Accelerator intelligence works